

SW43

Chemical Properties


CAS No. : 1421931-15-8

Formula: C₂₇H₄₅N₃O₄

Molecular Weight: 475.66

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

| | |
|---------------|---|
| Description | SW43 is a selective ligand of sigma-2 receptor. |
| Targets(IC50) | Others |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.1023 mL | 10.5117 mL | 21.0234 mL |
| 5 mM | 0.4205 mL | 2.1023 mL | 4.2047 mL |
| 10 mM | 0.2102 mL | 1.0512 mL | 2.1023 mL |
| 50 mM | 0.042 mL | 0.2102 mL | 0.4205 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ludwig JM, Xing M, Gai Y, Sun L, Zeng D, Kim HS. Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. *Mol Pharm*. 2017 Aug 7;14(8):2824-2830. doi: 10.1021/acs.molpharmaceut.7b00336. Epub 2017 Jul 25. PubMed PMID: 28700244.

McDonald ES, Mankoff J, Makvandi M, Chu W, Chu Y, Mach RH, Zeng C. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells. *Biochem Biophys Res Commun*. 2017 May 6;486(3):788-795. doi: 10.1016/j.bbrc.2017.03.122. Epub 2017 Mar 24. PubMed PMID: 28347815.

Ludwig JM, Gai Y, Sun L, Xiang G, Zeng D, Kim HS. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation. *Mol Oncol*. 2016 Aug;10(7):1133-45. doi: 10.1016/j.molonc.2016.05.003. Epub 2016 May 21. PubMed PMID: 27262893; PubMed Central PMCID: PMC4972658.

Hashim YM, Spitzer D, Vangveravong S, Hornick MC, Garg G, Hornick JR, Goedegebuure P, Mach RH, Hawkins WG. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. *Mol Oncol*. 2014 Jul;8(5):956-67. doi: 10.1016/j.molonc.2014.03.005. Epub 2014 Mar 26. PubMed PMID: 24731702; PubMed Central PMCID: PMC4082741.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481